60 Degrees Pharmaceuticals (SXTP) said Tuesday that the US Food and Drug Administration has no objections to its plan to import Kodatef, or tafenoquine, from Australia as a one-time precautionary measure to prevent potential short-term disruptions in the supply of Arakoda.
Both medications are identical antimalarials for the prophylaxis of malaria in adults 18 years and older, with Arakoda as the US brand and Kodatef as its Australian counterpart.
The company said it will import a five-month supply of Kodatef, while expanding Arakoda production to ensure uninterrupted tafenoquine availability for malaria prophylaxis to healthcare providers.
60 Degrees shares were up more than 6% in recent trading.
Price: 0.65, Change: +0.04, Percent Change: +6.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.